公开(公告)号：EP3087060A1

公开(公告)日：2016-11-02

申请号：EP14873215.9

申请日：2014-12-17

Applicant: Merck Sharp & Dohme Corp. ,  MSD R & D (China) Co. Ltd.

Inventor： SHEN, Dong-Ming ,  EGBERTSON, Melissa ,  BERGER, Richard ,  QIAN, XiaoXia ,  QIAN, Yimin ,  HARPER, Bart ,  YANG, Meng ,  GUO, Zack Zhi Qiang ,  RADA, Vanessa L. ,  WANG, Deping ,  CERNAK, Timothy A. ,  SINZ, Christopher J. ,  WANG, Ming ,  WILSON, Jonathan E. ,  XU, Shimin

IPC: C07D239/36 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  A61K31/513 ,  A61P25/18 ,  A61P25/22 ,  A61P25/28

CPC classification number: C07D239/36 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/06 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D413/04 ,  C07D417/04 ,  C07D487/04

Abstract: Disclosed are pyrimidine carboxamide compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2), pharmaceutical compositions and uses thereof.

Abstract translation: 公开了式（I）的嘧啶羧酰胺化合物，其可用作治疗与磷酸二酯酶2（PDE2）相关的中枢神经系统疾病，药物组合物及其用途的治疗剂。

公开(公告)号：EP3087060B1

公开(公告)日：2020-05-13

申请号：EP14873215.9

申请日：2014-12-17

Applicant: Merck Sharp & Dohme Corp. ,  MSD R&D (China) Co., Ltd.

Inventor： SHEN, Dong-Ming ,  EGBERTSON, Melissa ,  BERGER, Richard ,  QIAN, XiaoXia ,  QIAN, Yimin ,  HARPER, Bart ,  YANG, Meng ,  GUO, Zack Zhi Qiang ,  RADA, Vanessa L. ,  WANG, Deping ,  CERNAK, Timothy A. ,  SINZ, Christopher J. ,  WANG, Ming ,  WILSON, Jonathan E. ,  XU, Shimin

IPC: C07D239/36 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  A61K31/513 ,  A61P25/18 ,  A61P25/22 ,  A61P25/28

公开(公告)号：EP3054945B1

公开(公告)日：2018-08-15

申请号：EP14852979.5

申请日：2014-10-06

Applicant: Merck Sharp & Dohme Corp.

Inventor： WILSON, Jonathan E. ,  VACHAL, Petr ,  KURUKULASURIYA, Ravi

IPC: C07D209/24 ,  A61K31/404 ,  A61P9/10

CPC classification number: C07D209/12 ,  A61K31/404 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/5377 ,  A61K45/06 ,  C07D209/10 ,  C07D209/14 ,  C07D209/18 ,  C07D209/24 ,  C07D401/04 ,  C07D401/06 ,  C07D401/10 ,  C07D403/10 ,  C07D405/12 ,  C07D413/10 ,  C07D417/06 ,  C07D491/107

Abstract: 3,3′-Disubstituted indoline compounds, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.

公开(公告)号：EP3270926A1

公开(公告)日：2018-01-24

申请号：EP16765473.0

申请日：2016-03-11

Applicant: Merck Sharp & Dohme Corp.

Inventor： SHEN, Dong-Ming ,  SINZ, Christopher J. ,  CRESPO, Alejandro ,  WILSON, Jonathan E. ,  MCCRACKEN, Troy ,  XU, Shimin ,  LI, Haitang

IPC: A61K31/513 ,  C07D401/04 ,  C07D401/14

CPC classification number: C07D403/04 ,  A61P25/00 ,  C07D471/04 ,  C07D487/04 ,  C07D498/04

Abstract: The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

公开(公告)号：EP3054945A1

公开(公告)日：2016-08-17

申请号：EP14852979.5

申请日：2014-10-06

Applicant: Merck Sharp & Dohme Corp.

Inventor： WILSON, Jonathan E. ,  VACHAL, Petr ,  KURUKULASURIYA, Ravi

IPC: A61K31/404 ,  C07D209/02 ,  C07D209/04

CPC classification number: C07D209/12 ,  A61K31/404 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/5377 ,  A61K45/06 ,  C07D209/10 ,  C07D209/14 ,  C07D209/18 ,  C07D209/24 ,  C07D401/04 ,  C07D401/06 ,  C07D401/10 ,  C07D403/10 ,  C07D405/12 ,  C07D413/10 ,  C07D417/06 ,  C07D491/107

Abstract: 3,3′-Disubstituted indoline compounds, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.

Abstract translation: 包括化合物的药学上可接受的盐的3,3'-二取代二氢吲哚化合物是CETP抑制剂，可用于升高HDL-胆固醇，降低LDL-胆固醇，以及用于治疗或预防动脉粥样硬化。